-
CLEC5A and ISG20: Causal Signals in Atherosclerosis
2026-08-24
Zhang et al. integrated GEO expression data, eQTL evidence, Mendelian randomization, and model-based validation to investigate genes associated with atherosclerosis. The study identifies CLEC5A and ISG20 as positively associated with disease risk and provides experimental evidence that ISG20 is elevated in macrophage- and endothelial-rich plaque environments, supporting further investigation of its role in lipid accumulation and inflammation.
-
Epacadostat (INCB024360) Assay Workflows
2026-08-24
Build a practical IDO1 workflow around Epacadostat (INCB024360), from recombinant enzyme testing to standardized whole-blood cytokine profiling. The approach connects target engagement, immune-metabolic modulation, and checkpoint-combination studies while providing clear controls and troubleshooting guidance.
-
Promethazine HCl: Macrophage Assay Workflows
2026-08-23
Promethazine HCl is a practical probe for separating histamine H1 receptor effects from ROS-, lysosome-, and autophagy-linked macrophage responses. This workflow translates phenothiazine research into concentration, control, readout, and troubleshooting strategies for inflammation and host-directed antibacterial studies.
-
Pollen Interference in Hazardous Bioaerosol EEM
2026-08-22
This study shows that pollen can distort excitation–emission matrix fluorescence classification of hazardous bioaerosol components and evaluates spectral transformations to reduce that interference. Fast Fourier transform processing combined with random forest classification improved recognition, supporting more reliable rapid screening of suspected biological hazards.
-
CTP Solution and the Next Wave of mRNA Oncology
2026-08-22
A translational perspective on how Cytidine-5'-triphosphate quality supports in vitro mRNA production and how the p21 mRNA–LNP bladder cancer study informs localized oncology development without overstating what the evidence proves.
-
G-15 in Reliable GPR30 Assays
2026-08-21
A scenario-based guide to using G-15 (SKU B5469) as a selective GPR30 antagonist in cell proliferation, viability, calcium-mobilization, and PI3K/Akt experiments. The article emphasizes controls, stock preparation, endpoint interpretation, and practical product-selection criteria for reproducible estrogen signaling research.
-
Aurora A Targeting Beyond the Product Page
2026-08-20
Aurora A is emerging as a mechanistically relevant vulnerability in tumors shaped by mitotic stress, RB1 loss, and MYCN dysregulation. This thought-leadership guide connects recent retinoblastoma evidence with practical use of MK-8745, a potent and selective Aurora A inhibitor, for cell-cycle, apoptosis, lymphoma, and xenograft research while emphasizing model selection, translational limits, and reproducible assay design.
-
Idoxuridine Workflows for Viral DNA Research
2026-08-20
Build reproducible viral DNA synthesis assays with Idoxuridine, a traceable nucleoside analog suited to mechanism studies and herpes simplex virus research. This guide combines solvent-aware handling, time-course design, orthogonal readouts, and carefully bounded insights from human-neuron research.
-
Arctigenin at the Macrophage–Tumor Interface
2026-08-19
(-)-Arctigenin offers translational researchers a way to interrogate convergent NF-κB and MEK1 biology at the tumor–immune interface. This thought-leadership analysis connects macrophage-derived extracellular vesicle signaling in breast cancer with practical assay design, product selection, and the evidence boundaries that should shape future validation.
-
BIRB 796: Reframing p38α Inhibition
2026-08-19
BIRB 796 (Doramapimod) offers translational researchers a highly selective allosteric approach to p38α MAPK inhibition. This thought-leadership perspective connects its signaling biology, assay design, formulation considerations, inflammatory disease evidence, and emerging insights into inhibitor-directed dephosphorylation.
-
O6-Benzylguanine: MGMT Inhibitor Workflows
2026-08-18
O6-Benzylguanine provides a direct chemical route to MGMT inhibition, helping researchers test why alkylating agents fail in resistant cancer models. This practical guide connects stock preparation, combination-treatment design, DNA-damage readouts, and the AP-2α/MGMT findings reported in recurrent glioblastoma.
-
Dabigatran Etexilate: Oral Thrombin Inhibition
2026-08-18
This review examines how dabigatran etexilate established oral direct thrombin inhibition as a practical alternative to therapies requiring injections or intensive INR monitoring. The reference paper integrates pharmacology, pharmacokinetics, clinical efficacy, safety, and dosing considerations across venous thromboembolism and nonvalvular atrial fibrillation.
-
Cediranib (AZD2171) for VEGFR Assays
2026-08-17
Cediranib (AZD2171) enables mechanism-focused studies of VEGFR signaling, angiogenesis, and downstream PI3K/Akt/mTOR signaling inhibition. Its greatest experimental value emerges when target-proximal phosphorylation data are paired with separate measurements of growth arrest and cell death.
-
Substance P: Applied Tachykinin Workflows
2026-08-17
Build more reproducible pain transmission research and neuroimmune assays with a water-soluble Substance P peptide designed for controlled receptor stimulation. This guide combines practical preparation and response-measurement workflows with a data-quality strategy adapted from fluorescence-based interference research.
-
TPCA-1: Mapping IKK-2 to Inflammatory Cell Fate
2026-08-16
TPCA-1 is a highly selective IKK-2 inhibitor for dissecting NF-κB-driven cytokine programs, inflammatory disease biology, and the boundary between inflammatory transcription and RIPK1-regulated cell death.